Avicena to Be Featured on the Nationally Syndicated Television Series, Heartbeat of America, on July 20, 2007

Avicena to Be Featured on the Nationally Syndicated Television Series, Heartbeat of America, on July 20, 2007

Avicena Receives 'Keeping America Strong' Award

PALO ALTO, Calif., July 18 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (BULLETIN BOARD: AVGO) , a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that an interview with the Company's CEO, Dr. Belinda Tsao-Nivaggioli, will be featured on "Keeping America Strong," a nationally syndicated television show, on July 20, 2007. The series highlights U.S. companies that are making a significant contribution to business innovation in America.

During the interview Dr. Nivaggioli will elaborate on Avicena's neurology and dermaceutical programs to address the unmet needs of the aging U.S. population. In addition to the 30 minute episode featuring Avicena, the company was presented with the "Keeping America Strong" award, acknowledging the Company's innovative pipeline of late stage neurological drugs.

"I appreciated the opportunity to accept the 'Keeping America Strong' award on behalf of Avicena, as well as the occasion to discuss our unique development strategy and late-stage pharmaceutical program," said Dr. Tsao- Nivaggioli. "As R&D costs continue to rise, Avicena has managed costs and developed a strong late-stage pipeline through strategic collaborations with third parties, such as government and non-profit organizations. We're currently conducting a Phase III efficacy trial of our Parkinson's Disease drug, PD-02, in collaboration with the NIH's National Institute of Neurological Disorders and Stroke. The trial is being funded by a grant from the NIH and is one of the largest Parkinson's disease trials ever conducted."

ABOUT AVICENA

Avicena Group, Inc. is a Palo Alto, California-based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the company's public filings with the Securities and Exchange Commission for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the stage of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Contact:

The Ruth Group (on behalf of Avicena Group)
Stephanie Carrington / Sara Ephraim / (investors)
(646) 536-7029 / 7002
scarrington@theruthgroup.com / sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)
(646) 536-7033 / 7025
jmccargo@theruthgroup.com / jrando@theruthgroup.com

Source: Avicena Group, Inc.

CONTACT: Investors, Stephanie Carrington, +1-646-536-7029,
scarrington@theruthgroup.com, or Sara Ephraim, +1-646-536-7002,
sephraim@theruthgroup.com, or Media, Janine McCargo, +1-646-536-7033,
jmccargo@theruthgroup.com, or Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, all of The Ruth Group on behalf of Avicena Group

-------
Profile: intent